According to Morningstar, the companies entered into a royalty-free license agreement that will provide Alexion ample time and opportunity to continue converting their rare disease patents from Soliris to next-generation Ultomiris.If Alexion does achieve the earnings growth that analysts expect, and the company trades at a market neutral P/E ratio of 15, investors stand to generate 27% plus annualized rates of return out to 2022.